{"organizations": [], "uuid": "0698bd8441edfd22cadaad5170d0f85b0600463b", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-affimed-reports-new-data-for-afm13/brief-affimed-reports-new-data-for-afm13-from-two-separate-clinical-trials-idUSASB0C3JJ", "country": "US", "domain_rank": 408, "title": "BRIEF-Affimed Reports New Data For AFM13 From Two Separate Clinical Trials", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-02-01T15:39:00.000+02:00", "replies_count": 0, "uuid": "0698bd8441edfd22cadaad5170d0f85b0600463b"}, "author": "", "url": "https://www.reuters.com/article/brief-affimed-reports-new-data-for-afm13/brief-affimed-reports-new-data-for-afm13-from-two-separate-clinical-trials-idUSASB0C3JJ", "ord_in_thread": 0, "title": "BRIEF-Affimed Reports New Data For AFM13 From Two Separate Clinical Trials", "locations": [], "entities": {"persons": [{"name": "reu", "sentiment": "negative"}, {"name": "hodgkin", "sentiment": "none"}], "locations": [], "organizations": [{"name": "hodgkin lymphoma", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": " 40 PM / in 8 minutes BRIEF-Affimed Reports New Data For AFM13 From Two Separate Clinical Trials Reuters Staff 1 Min Read \nFeb 1 (Reuters) - Affimed Nv: \n* AFFIMED REPORTS NEW DATA FOR AFM13 FROM TWO SEPARATE CLINICAL TRIALS IN HODGKIN AND CD30-POSITIVE LYMPHOMAS \n* AFFIMED NV - ‍DATA DEMONSTRATE THAT AFM13 WAS WELL-TOLERATED​ \n* AFFIMED NV - ‍DATA DEMONSTRATE AFM13 IN COMBINATION WITH KEYTRUDA® (PEMBROLIZUMAB) DOUBLED COMPLETE RESPONSE RATE IN HODGKIN LYMPHOMA PATIENTS​ \n* AFFIMED NV - ‍EARLY DATA SUGGEST NEW OPPORTUNITY FOR AFM13 IN CD30-POSITIVE LYMPHOMA​ \n* AFFIMED NV - ‍AFM13 IS CLINICALLY ACTIVE AND WELL-TOLERATED AS MONO- AND COMBINATION THERAPY​ \n* AFFIMED NV - ‍ AFM13 IN COMBINATION WITH KEYTRUDA WAS WELL-TOLERATED WITH MOST OF ADVERSE EVENTS OBSERVED MILD TO MODERATE IN NATURE Source text for Eikon:  ", "external_links": [], "published": "2018-02-01T15:39:00.000+02:00", "crawled": "2018-02-01T15:51:08.001+02:00", "highlightTitle": ""}